Intelligent Systems Corp INS
Grizzly argues INS's sudden 2018 revenue surge is a round-trip scheme via undisclosed related-party shells in India run by employees; fair value is ~$5, 85% below $34.
Thesis
Grizzly Research argues that Intelligent Systems Corp's parabolic 2018 revenue and EBITDA surge — which management attributed to organic demand — was achieved through undisclosed related-party transactions with a web of Indian shell companies controlled by INS employees and their business partners. The firm documents a $235,000 convertible loan from CoreCard (INS's subsidiary) to Flexopt Technology, a startup founded by INS India director Anupam Pathak and partner Kapil Godani, immediately followed by Flexopt signing a processing agreement with CoreCard — a textbook round-trip. The relationship map extends to New Vision, Globe Teleservices, and UTS, all tied back to INS employees. Secondary red flags include a tiny auditor (Nichols, Cauley) whose only public client is INS, and board member Parker Petit, implicated in the MiMedx fraud. Price target: $5, roughly 85% downside from $33.94.
SCQA
Intelligent Systems Corp is a small-cap NYSE payments company whose CoreCard subsidiary saw revenues grow triple-digits YOY and EBIT margins swing from negative to 30%+ over three quarters starting early 2018, quintupling the stock.
Grizzly's forensic research shows the growth coincided with a $235K loan to Flexopt — an Indian FinTech founded by INS employees — that promptly round-tripped cash back via a processing agreement, with a wider related-party network uncovered.
Avoid or short the stock: related-party transactions were never disclosed, the auditor is a two-client shop, and board member Parker Petit is already implicated in the MiMedx fraud; Grizzly deems the equity uninvestable.
Grizzly assigns INS a price target of $5, implying roughly 85% downside from the $33.94 share price as of May 29, 2019, once the scheme is recognized by the market.
The three reasons
- 1
INS loaned $235K to a startup run by its own employees, then bought services back
- 2
Flexopt used INS's loan to pay another shell (New Vision) also owned by INS staff
- 3
Auditor Nichols Cauley has only one public client; board includes MiMedx fraud figure Parker Petit
Primary demands
- Avoid or sell INS common stock
- Disclose related-party transactions with Indian shell network
- Subject INS revenue recognition to auditor/SEC scrutiny
KPIs cited
Pattern membership
Precedents cited
- MiMedx (MDXG) fraud involving Parker Petit
- Aurelius Value short report on INS
Composition what's on the 26 slides
Slide gallery ·
Notes
Filename '2025-11-INS.pdf' refers to internal corpus index; publication date from cover is May 30, 2019. Short-seller report (Grizzly is a short-biased research shop); classified as research_note per schema guidance. Complements Aurelius Value's prior INS short report — Grizzly explicitly positions its findings as non-overlapping corroboration. No DCF/multiples shown for the $5 price target — asserted as consequence of fraud, not valuation math (valuation_frameworks='not_shown'). Document is Word-style prose with a bear-logo header; charts are vendor-generated (YCharts) rather than custom visx. Key visual asset is the p.23 stick-figure relationship diagram and p.26 appendix relationship map — genuine craft highlights in an otherwise text-heavy note.